Kentucky Retirement Systems Has $2.81 Million Stake in Cencora, Inc. (NYSE:COR)

Kentucky Retirement Systems reduced its stake in Cencora, Inc. (NYSE:COR) by 0.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 12,475 shares of the company’s stock after selling 99 shares during the quarter. Kentucky Retirement Systems’ holdings in Cencora were worth $2,811,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC bought a new stake in shares of Cencora during the 4th quarter worth $244,000. Trust Co. of Vermont bought a new stake in Cencora during the fourth quarter valued at about $62,000. Wahed Invest LLC acquired a new stake in shares of Cencora in the fourth quarter valued at about $567,000. Vanguard Group Inc. bought a new position in shares of Cencora in the fourth quarter worth about $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new position in shares of Cencora during the 4th quarter worth about $3,307,000. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Robert W. Baird dropped their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Bank of America reissued a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Finally, StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.67.

Cencora Stock Performance

NYSE:COR opened at $228.11 on Friday. The firm has a market capitalization of $45.50 billion, a PE ratio of 24.96, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 12-month low of $178.21 and a 12-month high of $247.66. The firm has a 50-day moving average price of $234.84 and a 200 day moving average price of $233.13.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter last year, the company earned $2.92 EPS. Cencora’s revenue was up 10.8% on a year-over-year basis. Research analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.89%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.

Insider Buying and Selling

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock worth $1,070,392,799 in the last quarter. 15.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.